Boston Therapeutics Obtains Financing for International Trial

Boston Therapeutics (OTCQB:BTHE) announced the complete funding for a new phase II/III BTI320 trial on type 2 diabetic patients, in partnership with Advance Pharmaceutical Company Limited.
As quoted in the press release:

The study will initiate as soon as drug supply is processed and will ultimately include 300 T2D patients currently on anti-diabetic regimen. Recruitment will initiate at the Joslin Diabetes Center, Boston, MA, and will be joined by its former trial center form the Chinese University of Hong Kong (CUHK) which has also been confirmed. The plans anticipate up to 10 additional institutions from the US and greater China.
The post-prandial hyper-glycemia (blood glucose rapid increase) still remains a problem in the management of type 2 diabetes. Increase in these fluctuations exacerbates oxidative stress, a well-known problem and precursor to many metabolic disease states.

Click here to read the full press release.

Source: www.marketwired.com